{"filing":{"accession_number":"0000914475-26-000035","cik":"0000914475","ticker":"NBIX","company_name":"NEUROCRINE BIOSCIENCES INC","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"nbix-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000035/nbix-20260730.htm"},"events":[{"id":22535,"run_id":20389,"accession_number":"0000914475-26-000035","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Neurocrine Biosciences' second-quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2026\" with the full press release attached as Exhibit 99.1. The press release presents comprehensive quarterly financial data including total revenues of $959 million (39% YoY growth), GAAP net income of $144 million, and updated full-year 2026 guidance, along with product-specific sales figures and clinical developments.","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22507,"accession_number":"0000914475-26-000035","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Neurocrine Biosciences' second-quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2026\" with the full press release attached as Exhibit 99.1. The press release presents comprehensive quarterly financial data including total revenues of $959 million (39% YoY growth), GAAP net income of $144 million, and updated full-year 2026 guidance, along with product-specific sales figures and clinical developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:17:32.811387+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22507,"accession_number":"0000914475-26-000035","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Neurocrine Biosciences' second-quarter 2026 financial results. The filing explicitly states \"On July 30, 2026, Neurocrine Biosciences, Inc. announced its financial results for the second quarter ended June 30, 2026\" with the full press release attached as Exhibit 99.1. The press release presents comprehensive quarterly financial data including total revenues of $959 million (39% YoY growth), GAAP net income of $144 million, and updated full-year 2026 guidance, along with product-specific sales figures and clinical developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:17:32.811387+00:00","company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","filing_date":"2026-07-30"}]}